Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$0.985
−HK$0.02 · -1.99%
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
Latest quote
HK$0.985
−HK$0.02 · -1.99%
Regular session · HKT · Market data may be delayed.
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
52-week range
Current HK$0.985
Regular session · HKT · Market data may be delayed.
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
52-week range
Current HK$0.985
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.23B CNY | 1.06B CNY | 1.15B CNY | 1.28B CNY | 1.17B CNY |
| Cost of goods sold | 673.47M CNY | 482.68M CNY | 509.63M CNY | 511M CNY | 489.79M CNY |
| Gross profit | 557.4M CNY | 577.63M CNY | 641.52M CNY | 766.68M CNY | 675.36M CNY |
| Research and development | 83.48M CNY | 70.83M CNY | 90.81M CNY | 79.48M CNY | 67.03M CNY |
| Selling, general, and administrative | 244.27M CNY | 254.5M CNY | 260.26M CNY | 264.79M CNY | 226.44M CNY |
| Operating expenses | 327.75M CNY | 209.72M CNY | 199.2M CNY | 344.27M CNY | 293.47M CNY |
| Interest income | 30.26M CNY | 36.42M CNY | 25.93M CNY | 19.38M CNY | 19.81M CNY |
| Interest expense | 496K CNY | 3.61M CNY | 989K CNY | 371K CNY | 641K CNY |
| Depreciation and amortization | 116.24M CNY | 78.44M CNY | 83.89M CNY | 66.41M CNY | 53.13M CNY |
| Operating income | 229.65M CNY | 367.91M CNY | 277.42M CNY | 422.41M CNY | 380.76M CNY |
| Net income | 213.97M CNY | 564.94M CNY | 326M CNY | 358.06M CNY | 358.18M CNY |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.095
2025 complete year+46.2% since 2021
2026 partial: HK$0.048
HK$0.065
2,021
HK$0.08
2,022
HK$0.088
2,023
HK$0.08
2,024
HK$0.095
2,025
HK$0.048
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Sep 22, 2026 | HK$0.015Semi-Annual | Sep 24, 2026 | Oct 9, 2026 |
Dividend | May 27, 2026 | HK$0.048Annual | May 29, 2026 | Jun 12, 2026 |
Dividend | Sep 16, 2025 | HK$0.015Annual | Sep 18, 2025 | Oct 3, 2025 |
Dividend | May 27, 2025 | HK$0.08Special | May 29, 2025 | Jun 12, 2025 |
Dividend | Sep 16, 2024 | HK$0.015Semi-Annual | Sep 18, 2024 | Oct 3, 2024 |
Dividend | May 28, 2024 | HK$0.065Semi-Annual | May 30, 2024 | Jun 12, 2024 |
Ex-dividend Sep 22, 2026
HK$0.015
Semi-Annual
Record Sep 24, 2026 · Payment Oct 9, 2026
Ex-dividend May 27, 2026
HK$0.048
Annual
Record May 29, 2026 · Payment Jun 12, 2026
Ex-dividend Sep 16, 2025
HK$0.015
Annual
Record Sep 18, 2025 · Payment Oct 3, 2025
Ex-dividend May 27, 2025
HK$0.08
Special
Record May 29, 2025 · Payment Jun 12, 2025
Ex-dividend Sep 16, 2024
HK$0.015
Semi-Annual
Record Sep 18, 2024 · Payment Oct 3, 2024
Ex-dividend May 28, 2024
HK$0.065
Semi-Annual
Record May 30, 2024 · Payment Jun 12, 2024
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
